Raiffeisen Bank International AG Grows Position in DexCom, Inc. (NASDAQ:DXCM)

Key Points

• Raiffeisen Bank International AG increased its stake in DexCom, Inc. by 17.0% during Q1, acquiring 3,894 shares and bringing its total holdings to 26,760 shares worth approximately $1.81 million.
• Insider sales included Sadie Stern selling 1,466 shares at $88.99, and Nicholas Augustinos selling 3,672 shares at $82.80, indicating a slight decrease in their ownership positions.
• DexCom reported a quarterly revenue of $1.16 billion, exceeding analysts' expectations, and recorded earnings per share of $0.48, up from $0.43 during the same period last year.

Raiffeisen Bank International AG lifted its holdings in shares of DexCom, Inc. (NASDAQ:DXCM - Free Report) by 17.0% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 26,760 shares of the medical device company's stock after buying an additional 3,894 shares during the quarter. Raiffeisen Bank International AG's holdings in DexCom were worth $1,813,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of DXCM. Blair William & Co. IL boosted its holdings in DexCom by 0.3% in the first quarter. Blair William & Co. IL now owns 2,238,563 shares of the medical device company's stock valued at $152,871,000 after purchasing an additional 5,916 shares during the period. Bank of Nova Scotia raised its holdings in shares of DexCom by 246.6% in the first quarter. Bank of Nova Scotia now owns 931,479 shares of the medical device company's stock valued at $63,611,000 after buying an additional 662,739 shares during the last quarter. Banco Santander S.A. lifted its position in DexCom by 2.3% during the 1st quarter. Banco Santander S.A. now owns 196,308 shares of the medical device company's stock worth $13,406,000 after acquiring an additional 4,349 shares during the period. OVERSEA CHINESE BANKING Corp Ltd increased its stake in DexCom by 579.0% in the 1st quarter. OVERSEA CHINESE BANKING Corp Ltd now owns 46,543 shares of the medical device company's stock valued at $3,176,000 after buying an additional 39,688 shares during the period. Finally, PNC Financial Services Group Inc. raised its holdings in DexCom by 11.1% during the first quarter. PNC Financial Services Group Inc. now owns 51,828 shares of the medical device company's stock worth $3,539,000 after purchasing an additional 5,159 shares in the last quarter. 97.75% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

DXCM has been the topic of a number of recent analyst reports. Mizuho upped their price target on shares of DexCom from $95.00 to $100.00 and gave the stock an "outperform" rating in a research note on Wednesday, July 16th. Piper Sandler upped their target price on shares of DexCom from $90.00 to $100.00 and gave the company an "overweight" rating in a report on Thursday, July 31st. Canaccord Genuity Group restated a "buy" rating and issued a $106.00 target price on shares of DexCom in a report on Friday, August 1st. The Goldman Sachs Group started coverage on shares of DexCom in a research note on Friday, May 30th. They issued a "buy" rating and a $104.00 target price on the stock. Finally, William Blair upgraded DexCom to a "strong-buy" rating in a research note on Thursday, July 31st. Four investment analysts have rated the stock with a hold rating, fifteen have given a buy rating and four have given a strong buy rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of "Buy" and an average target price of $99.89.

DexCom Stock Performance

NASDAQ:DXCM remained flat at $76.40 during mid-day trading on Thursday. The company had a trading volume of 3,067,729 shares, compared to its average volume of 3,640,460. DexCom, Inc. has a 1-year low of $57.52 and a 1-year high of $93.25. The company has a debt-to-equity ratio of 0.48, a current ratio of 1.52 and a quick ratio of 1.35. The stock has a market cap of $29.96 billion, a PE ratio of 53.06, a price-to-earnings-growth ratio of 1.60 and a beta of 1.43. The stock's fifty day moving average price is $83.83 and its 200-day moving average price is $80.42.

DexCom (NASDAQ:DXCM - Get Free Report) last issued its quarterly earnings results on Wednesday, July 30th. The medical device company reported $0.48 earnings per share for the quarter, topping analysts' consensus estimates of $0.45 by $0.03. DexCom had a net margin of 13.29% and a return on equity of 30.41%. The company had revenue of $1.16 billion during the quarter, compared to the consensus estimate of $1.13 billion. During the same quarter in the prior year, the firm posted $0.43 EPS. The firm's quarterly revenue was up 15.2% on a year-over-year basis. On average, analysts predict that DexCom, Inc. will post 2.03 EPS for the current fiscal year.

Insider Buying and Selling at DexCom

In other DexCom news, Director Nicholas Augustinos sold 3,672 shares of the firm's stock in a transaction on Monday, June 16th. The shares were sold at an average price of $82.80, for a total value of $304,041.60. Following the completion of the sale, the director directly owned 33,411 shares in the company, valued at approximately $2,766,430.80. This trade represents a 9.90% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, EVP Sadie Stern sold 1,466 shares of the company's stock in a transaction that occurred on Monday, July 28th. The stock was sold at an average price of $88.99, for a total value of $130,459.34. Following the transaction, the executive vice president directly owned 106,689 shares in the company, valued at approximately $9,494,254.11. This trade represents a 1.36% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 28,656 shares of company stock valued at $2,412,191. 0.32% of the stock is owned by insiders.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.